To answer fiona_VT's question specifically:
From a clinical standpoint, GIP receptor pharmacology is an area where we have good evidence.
The short answer: baseline labs + quarterly monitoring is the standard of care.
The longer answer involves understanding the mechanism of action at the receptor level, which I am happy to elaborate on if helpful.
Slightly tangential to GIP receptor pharmacology but mia_MS2 reminded me — has anyone else noticed changes in their alcohol tolerance?
I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.
OP here — wow, did not expect this much response! Thank you all for the thoughtful replies on GIP receptor pharmacology.
To answer Dr.RaviCardio: I started tracking everything in a spreadsheet from day 1.
Quick update: I will post a proper update thread soon. Thanks again for the evidence-based discussion — this is exactly why I posted in a science-based community. 🙏
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesWant to share my personal experience related to GIP receptor pharmacology since I think it might help others in a similar situation.
I started my GLP-1 journey in March 2025 at 262 lbs with metabolic syndrome. My telehealth provider prescribed semaglutide 0.25mg to start.
Now, 8 months later: I am down 37 lbs, my labs have normalized, and my sleep apnea has improved dramatically. The GIP receptor aspect specifically was something that made a big difference in my journey.
This forum was my go-to resource throughout.
Relevant to GIP receptor pharmacology — here is my latest bloodwork comparison:
Key improvements: A1C 8.0% → 5.3%, triglycerides 223 → 93 mg/dL, hsCRP 6.0 → 1.1 mg/L. All on tirzepatide for 15 months.
The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.